Hepatitis b drug trial halted early
NCT ID NCT02797522
First seen Jan 12, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This early-stage study tested an experimental drug called ARC-521 in healthy volunteers and people with chronic hepatitis B. The goal was to check safety and how the body processes the drug. The study was terminated early, so results are limited. It involved 47 participants and was sponsored by Arrowhead Pharmaceuticals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site 1
Grafton, Auckland, 1011, New Zealand
Conditions
Explore the condition pages connected to this study.